Viewing nowCombinationTuberotong 30/5 mg (Pimasartan Potassium, Rosuvastatin)
Fimasartan Potassium Trihydrate Granules 75mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.

MFDS item code 201605337 · Approved 2016.08.31 · Insurance code 641906560
Treatment of hypertension; improves dyslipidemia; inhibits the progression of atherosclerosis and reduces cardiovascular risk
This drug is used for patients who need to take both Pimasartan and Rosuvastatin simultaneously. Pimasartan is mainly used to control blood pressure in patients with essential hypertension. Rosuvastatin helps lower cholesterol levels in patients with hypercholesterolemia who are not controlled by diet and exercise. Additionally, it slows the progression of atherosclerosis and reduces the risk of cardiovascular disease. It particularly reduces the risk of stroke, myocardial infarction, and vascular revascularization in middle-aged individuals with high-sensitive C-reactive protein levels. Therefore, this drug is used for the treatment of patients with both hypertension and hyperlipidemia.
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, fimasartan and rosuvastatin. ○ Fimasartan 1. Adults The recommended dose of this medicine is 30~60 mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, the dose may be increased to 120 mg once daily. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum after approximately 8 weeks~12 weeks. 2. Older adults No initial dose adjustment is required in older adults aged 70 years or younger. (Refer to section 9. Administration to Older Adults under Precautions for Use.) 3. Patients with renal impairment No dose adjustment is required in patients with mild~moderate renal impairment (creatinine clearance 30~80 mL/min). In patients with severe renal impairment (creatinine clearance < 30 mL/min), however, treatment should be initiated at 30 mg once daily, and the dose should not exceed 60 mg per day. 4. Patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment. This medicine should not be administered to patients with moderate~severe hepatic impairment. (Refer to sections 2. Patients Who Must Not Be Treated with This Medicine and 10. Administration to Patients with Hepatic Impairment under Precautions for Use.) 5. Patients with reduced effective circulating blood volume (e.g., patients taking high doses of diuretics) For patients at high risk of hypotension, such as those with reduced effective circulating blood volume, an initial dose of 30 mg once daily is recommended. (Refer to section 3. Administration with Caution under Precautions for Use.) ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 mg per day. 2. Older adults No dose adjustment is required. 3. Patients with renal impairment No dose adjustment is required in patients with mild or moderate renal impairment. This medicine should not be administered to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment Systemic exposure to rosuvastatin did not increase in patients with a Child-Pugh score of 7 or less, but it increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. This medicine should not be administered to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking fimasartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
This drug can cause serious harm to the fetus and newborn, especially during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately if pregnancy is confirmed. Women who are allergic to any components of this medicine or are pregnant or may become pregnant, as well as breastfeeding women, should not take this medicine. Patients with severe liver dysfunction, severely impaired kidney function, or specific muscle disorders should not take this medicine. Patients with low blood volume or salt depletion, impaired kidney function, or heart disease should be cautious when taking this medicine and should do so under medical supervision. This medicine can cause muscle-related side effects such as muscle pain, myopathy, and rarely rhabdomyolysis; if any abnormal symptoms in the muscles occur, it is essential to notify medical personnel immediately. Regular liver function tests and blood tests must be performed during treatment, and administration should be stopped if there are any abnormal symptoms in the liver or kidneys. As this medicine may interact with other drugs, it is necessary to inform a doctor or pharmacist, especially when taken in conjunction with potassium-sparing diuretics, lithium, non-steroidal anti-inflammatory drugs, certain antibiotics, antifungals, and immunosuppressants. The safety and efficacy of this drug in children and adolescents under 18 have not been established, and the elderly may be more sensitive to this drug, so caution is needed. Dizziness or drowsiness may occur while driving or operating machinery, so caution is advised. This drug should be kept out of reach of children, and it is recommended to avoid transferring it to other containers.
Dyspepsia, nausea, fever, hepatitis, headache, dizziness, fainting, sedation, migraine, vomiting, upper abdominal pain, weakness, foreign body sensation, elevated ALT, elevated γ-GTP, increased liver enzyme levels, increased white blood cell count, urination disorder, frequent urination, cough, hyperkalemia, arthralgia, insomnia, pruritus, angioedema, decreased platelet count, increased serum creatine phosphokinase, muscle contraction, musculoskeletal stiffness, localized urticaria, facial flushing, flushing, erectile dysfunction, constipation, abdominal pain, pancreatitis, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, Stevens-Johnson syndrome, eosinophilia and systemic symptoms associated drug reaction syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe myasthenia gravis, ocular myasthenia gravis, bruising, fainting, generalized pain, muscle cramps, gout, erectile dysfunction, chest pain, lower back pain, limb pain, peripheral edema, facial edema, fatigue, fever, neck/shoulder pain, fracture, arthrosis, osteoporosis, myalgia, pharyngitis, upper respiratory infection, sputum, rhinitis, nosebleed, bronchitis, sensory disturbances, numbness, tremor, hypertonia, anxiety, memory impairment, loss of appetite, gastroesophageal reflux, gastritis, functional gastrointestinal disorder, gastroenteritis, urinary incontinence, kidney stones, chronic renal failure exacerbation, cystitis, urinary tract infection, elevated BUN, pyelonephritis, otitis media, fungal infection, abscess, bacterial infection, genital herpes, cold sores, shingles, myeloproliferative disorder, anemia exacerbation, iron deficiency anemia, tinnitus, hearing impairment, hearing loss, pelvic inflammatory disease, vaginitis, uterine prolapse, benign prostatic hyperplasia, scrotal pain, blood pressure variability, fatty liver, localized inflammation, soft tissue infection, pulmonary embolism, lymphadenopathy, unspecified laceration, septal deviation, surgical intervention, postoperative pain, heat intolerance, recurrent cancer, fall
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly closed container to avoid exposure to air or moisture and should be kept at room temperature between 1 to 30 degrees Celsius. Storing it this way helps maintain the effectiveness of the medicine for a longer period.
White, convex, octagonal film-coated tablets
30 tablets/box [10 tablets/PTP packaging × 3], 100 tablets/box [10 tablets/PTP packaging × 10], 30 tablets/box [10 tablets/Alu-Alu packaging × 3], 100 tablets/box [10 tablets/Alu-Alu packaging × 10]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationFimasartan Potassium Trihydrate Granules 75mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate Granules 150mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Boryung Co., Ltd.
CombinationFimasartan Potassium Trihydrate Granules 150mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate Granules 300mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate Granules 75mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
Fimasartan Potassium Trihydrate Granules 75mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Boryung Biopharma Co., Ltd.
Fimasartan Potassium Trihydrate Granules 75mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Boryung Biopharma Co., Ltd.
Fimasartan Potassium Trihydrate Granules 150mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Boryung Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.